Merck Q2 Loss Looms Despite Keytruda Strength

Forward-Looking Analysis

Wall Street analysts project Merck will report a quarterly loss of -$0.26 to -$0.27 per share for Q2 2026, reflecting a year-over-year decline of approximately 112.2%. This forecast marks a significant deterioration from the $2.13 EPS recorded in the same quarter last year. Revenue is estimated at $16.33 billion, representing a modest 3.3% increase year-over-year. Although the consensus EPS estimate has seen a slight upward revision of 1.6% over the past 30 days, the anticipated loss contrasts sharply with the positive momentum seen in previous quarters. Key product performance is expected to drive specific metrics: Keytruda sales are forecast to reach $8.06 billion, a 1.3% increase, while Keytruda International sales are projected to grow 3.8% to $3.33 billion. Conversely, Lynparza alliance revenue is expected to decline 3.6% to $356.54 million, and Bridion U.S. sales may drop 20% to $328.80 million. Despite these headwinds in specific oncology and hospital acute care segments, analysts maintain a "Moderate Buy" rating based on 18 analysts, with the stock currently trading near its 52-week high at $113.87. The market is closely watching whether Keytruda's stability can offset losses in other portfolio areas to meet revenue targets.

Historical Performance Review

Merck’s Q1 2026 results demonstrated significant volatility, reporting $16.29 billion in revenue, which beat consensus estimates of $15.85 billion. However, profitability was severely impacted, with net income dropping to -$4.24 billion, a 243.1% decrease from the previous quarter. The GAAP EPS came in at -$1.72, though the reported EPS of -$1.28 still beat the consensus estimate of -$1.47 by $0.19. Gross profit was recorded at $12.09 billion, providing some margin stability despite the substantial net loss driven by non-operational factors or one-time charges.

Additional News

Merck has recently advanced its HIV pipeline and expanded Keytruda’s indications. On July 24, 2026, the company announced initial access plans for Alimatravir, an investigational once-monthly oral HIV pre-exposure prophylaxis in Phase 3 development. Additionally, data presented on July 15 showed that an investigational once-weekly oral HIV treatment regimen of Islatravir and Lenacapavir maintained virological suppression in adults switching antiretroviral therapy. In regulatory news, the FDA approved LIPFENDRA (enlicitide) on July 16 as the first and only once-daily oral PCSK9 inhibitor for reducing LDL-C in adults with hypercholesterolemia. Furthermore, Keytruda received approvals for new indications: in July, it was approved with Padcev for muscle-invasive bladder cancer, and in June, it was approved with Trodelvy for advanced triple-negative breast cancer. These developments highlight Merck’s focus on diversifying its therapeutic portfolio beyond oncology while strengthening its leadership in immunotherapy.

Summary & Outlook

Merck faces a challenging Q2 2026 with anticipated EPS losses and flat revenue growth, signaling near-term headwinds despite strong Keytruda performance. The sharp decline in net income and EPS from Q1 indicates underlying profitability pressures, potentially linked to R&D investments or one-time expenses. However, recent FDA approvals for LIPFENDRA and expanded Keytruda indications provide positive long-term growth catalysts. The stock’s position near its 52-week high suggests investor confidence in the pipeline, but the upcoming earnings report carries downside risk due to the expected loss. We maintain a neutral stance, advising caution until Q2 results clarify whether the loss is an isolated anomaly or a trend, balancing the robust oncology franchise against emerging competition in HIV and metabolic diseases.